TY - JOUR
T1 - Single-dose administration of a short-acting gonadotropin-releasing hormone agonist does not affect cycle outcome in frozen–thawed embryo transfer cycles
AU - Wang, Hanbi
AU - Tang, Xian
AU - Bukulmez, Orhan
AU - Deng, Chengyan
AU - Yu, Qi
AU - Zhou, Yuanzheng
AU - Sun, Zhengyi
AU - Zhen, Jingran
AU - Wang, Xue
AU - Liu, Meizhi
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - Objective: This prospective study aimed to assess the effect of short-acting gonadotropin-releasing hormone agonist (GnRHa) administration on pregnancy outcomes in frozen–thawed embryo transfer (FET) cycles. Methods: Patients who planned to have FET in Peking Union Medical College Hospital (China) were recruited for this study and randomly assigned into two groups. Patients in the experimental group (n = 460) received triptorelin acetate on the day of embryo transfer along with routine luteal support. Patients in the control group (n = 433) only received luteal support. One dose (0.1 mg) of a short-acting GnRHa was administered on the day of blastocyte transfer. The rates for clinical pregnancy, biochemical pregnancy, implantation, miscarriage, and ectopic pregnancy were compared between the groups. Results: There were no significant differences in the number and quality of blastocytes transferred between the two groups. In the experimental and control groups, the clinical pregnancy rate was 56.3% and 50.58%, the biochemical pregnancy rate was 15.78% and 18.94%, and the median implantation rate was 39.98% and 38.01%, respectively, with no significant difference between the groups. Biochemical pregnancy and abortion and the ectopic pregnancy rate were not significantly different between the two groups. Conclusion: In FET cycles, a GnRHa does not affect the pregnancy outcome.
AB - Objective: This prospective study aimed to assess the effect of short-acting gonadotropin-releasing hormone agonist (GnRHa) administration on pregnancy outcomes in frozen–thawed embryo transfer (FET) cycles. Methods: Patients who planned to have FET in Peking Union Medical College Hospital (China) were recruited for this study and randomly assigned into two groups. Patients in the experimental group (n = 460) received triptorelin acetate on the day of embryo transfer along with routine luteal support. Patients in the control group (n = 433) only received luteal support. One dose (0.1 mg) of a short-acting GnRHa was administered on the day of blastocyte transfer. The rates for clinical pregnancy, biochemical pregnancy, implantation, miscarriage, and ectopic pregnancy were compared between the groups. Results: There were no significant differences in the number and quality of blastocytes transferred between the two groups. In the experimental and control groups, the clinical pregnancy rate was 56.3% and 50.58%, the biochemical pregnancy rate was 15.78% and 18.94%, and the median implantation rate was 39.98% and 38.01%, respectively, with no significant difference between the groups. Biochemical pregnancy and abortion and the ectopic pregnancy rate were not significantly different between the two groups. Conclusion: In FET cycles, a GnRHa does not affect the pregnancy outcome.
KW - Gonadotropin-releasing hormone agonist
KW - abortion
KW - blastocyte
KW - frozen–thawed cycle
KW - in vitro fertilization–embryo transfer
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85105516919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105516919&partnerID=8YFLogxK
U2 - 10.1177/03000605211012247
DO - 10.1177/03000605211012247
M3 - Article
C2 - 33947255
AN - SCOPUS:85105516919
SN - 0300-0605
VL - 49
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 5
ER -